The 9 largest diabetes technology companies in the world
Aug 21, 2024 · Technologies from Abbott, Dexcom, Medtronic and Insulet. These companies are the four largest diabetes technology companies in the world. [Images courtesy of the companies] Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in …
Abbott, Dexcom settle global CGM patent litigation
Dec 23, 2024 · Left, the Dexcom G7 CGM. Right, the Abbott FreeStyle Libre 2. [Images from Dexcom and Abbott] Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies.
Insulet fully launches Omnipod 5 app for iPhone in U.S.
Oct 29, 2024 · The Omnipod 5 with the Dexcom G7 CGM. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) today announced the full market release of the Omnipod 5 automated insulin delivery app for iPhone in the U.S. Acton, Massachusetts-based Insulet now offers the app for free download from the Apple App Store.
These diabetes devices are set to launch in 2024 - Drug Delivery …
Feb 27, 2024 · The Stelo glucose monitor for people with diabetes who are not taking insulin. [Image courtesy of Dexcom] The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year.Some of those stories didn’t end in 2023, though ...
Qnovia wins FDA IND for nicotine inhaler for smoking cessation
Oct 2, 2024 · Qnovia’s nicotine replacement therapy device. [Image courtesy of Qnovia] Qnovia announced that the FDA cleared its investigational new drug (IND) application for the RespiRx smoking cessation inhaler (QN-01). RespiRx, a drug-device combination product, offers inhalable nicotine replacement therapy (NRT) to assist in the quitting of smoking.
Senseonics wins integrated CGM designation from FDA
Apr 30, 2024 · The Eversense E3 implantable CGM system. [Image from Ascensia/Senseonics] The FDA today granted integrated CGM (iCGM) designation to the Eversense continuous glucose monitoring system from Senseonics (NYSE:SENS). With this designation, Eversense becomes the first fully implantable device in the category.
BD hit with FDA warning related to Pyxis medication management
Dec 23, 2024 · The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of its $12 billion CareFusion acquisition in 2015.. The warning letter, dated Nov. 22 and posted on Dec. 17, involves inspections conducted in May at a former CareFusion facility in San Diego.
PreEvnt to unveil non-invasive blood glucose alert device
Jan 3, 2025 · The Isaac blood glucose alert device. [Image courtesy of PreEvnt] PreEvnt recently announced plans to introduce Isaac, its non-invasive alert device for monitoring blood glucose levels. Isaac, which is meant to monitor blood glucose levels using just the breath of the user, also has a custom phone app.
i2o looks to revive diabetes drug-eluting implant from Intarcia
Sep 5, 2023 · i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics.. The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move.
SpyGlass shares positive data for drug-eluting intraocular lens
Oct 18, 2024 · [Image from the SpyGlass Pharma website] SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery.